Literature DB >> 31484064

Structure and Functional Binding Epitope of V-domain Ig Suppressor of T Cell Activation.

Nishant Mehta1, Sainiteesh Maddineni1, Irimpan I Mathews2, R Andres Parra Sperberg1, Po-Ssu Huang3, Jennifer R Cochran4.   

Abstract

V-domain immunoglobulin (Ig) suppressor of T cell activation (VISTA) is an immune checkpoint protein that inhibits the T cell response against cancer. Similar to PD-1 and CTLA-4, a blockade of VISTA promotes tumor clearance by the immune system. Here, we report a 1.85 Å crystal structure of the elusive human VISTA extracellular domain, whose lack of homology necessitated a combinatorial MR-Rosetta approach for structure determination. We highlight features that make the VISTA immunoglobulin variable (IgV)-like fold unique among B7 family members, including two additional disulfide bonds and an extended loop region with an attached helix that we show forms a contiguous binding epitope for a clinically relevant anti-VISTA antibody. We propose an overlap of this antibody-binding region with the binding epitope for V-set and Ig domain containing 3 (VSIG3), a purported functional binding partner of VISTA. The structure and functional epitope presented here will help guide future drug development efforts against this important checkpoint target.
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  B7-H5; IGSF11; PD-1H; VISTA; VSIG3; cancer immunotherapy; checkpoint inhibitor; epitope mapping; high resolution crystal structure; yeast display

Mesh:

Substances:

Year:  2019        PMID: 31484064     DOI: 10.1016/j.celrep.2019.07.073

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  26 in total

Review 1.  Cytokines and costimulation in acute graft-versus-host disease.

Authors:  Geoffrey R Hill; Motoko Koyama
Journal:  Blood       Date:  2020-07-23       Impact factor: 22.113

2.  Considering B7-CD28 as a family through sequence and structure.

Authors:  Sean M West; Xiaodi A Deng
Journal:  Exp Biol Med (Maywood)       Date:  2019-06-17

Review 3.  VISTA: Coming of age as a multi-lineage immune checkpoint.

Authors:  M A ElTanbouly; E Schaafsma; R J Noelle; J L Lines
Journal:  Clin Exp Immunol       Date:  2020-02-04       Impact factor: 4.330

Review 4.  IGSF11 and VISTA: a pair of promising immune checkpoints in tumor immunotherapy.

Authors:  Xi-Yang Tang; Yan-Lu Xiong; Xian-Gui Shi; Ya-Bo Zhao; An-Ping Shi; Kai-Fu Zheng; Yu-Jian Liu; Tao Jiang; Nan Ma; Jin-Bo Zhao
Journal:  Biomark Res       Date:  2022-07-13

Review 5.  VISTA inhibitors in cancer immunotherapy: a short perspective on recent progresses.

Authors:  Chenyang Wu; Xin Cao; Xiaojin Zhang
Journal:  RSC Med Chem       Date:  2021-07-06

6.  VISTA is an acidic pH-selective ligand for PSGL-1.

Authors:  Linhui Julie Su; Jason Pinckney; David Critton; Robert J Johnston; Eric Boyer; Arathi Krishnakumar; Martin Corbett; Andrew L Rankin; Rose Dibella; Lynne Campbell; Gaelle H Martin; Hadia Lemar; Thomas Cayton; Richard Y-C Huang; Xiaodi Deng; Akbar Nayeem; Haibin Chen; Burce Ergel; Joseph M Rizzo; Aaron P Yamniuk; Sanjib Dutta; Justine Ngo; Andrea Olga Shorts; Radha Ramakrishnan; Alexander Kozhich; Jim Holloway; Hua Fang; Ying-Kai Wang; Zheng Yang; Kader Thiam; Ginger Rakestraw; Arvind Rajpal; Paul Sheppard; Michael Quigley; Keith S Bahjat; Alan J Korman
Journal:  Nature       Date:  2019-10-23       Impact factor: 49.962

7.  VISTA is an activating receptor in human monocytes.

Authors:  Bryan M Rogers; Laura Smith; Zoltan Dezso; Xu Shi; Enrico DiGiammarino; Denny Nguyen; Sunantha Sethuraman; Pingping Zheng; Donghee Choi; Dong Zhang; Andrew Nguyen; Kathleen McGuire; Wei Liu; Namjin Chung; Debra T Chao; Shiming Ye; Gabriel R Starbeck-Miller
Journal:  J Exp Med       Date:  2021-06-09       Impact factor: 14.307

Review 8.  The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead.

Authors:  Negar Hosseinkhani; Afshin Derakhshani; Mahdi Abdoli Shadbad; Antonella Argentiero; Vito Racanelli; Tohid Kazemi; Ahad Mokhtarzadeh; Oronzo Brunetti; Nicola Silvestris; Behzad Baradaran
Journal:  Front Immunol       Date:  2021-05-19       Impact factor: 7.561

9.  Expression of Immune Checkpoint Regulators IDO, VISTA, LAG3, and TIM3 in Resected Pancreatic Ductal Adenocarcinoma.

Authors:  Felix C Popp; Ingracia Capino; Joana Bartels; Alexander Damanakis; Jiahui Li; Rabi R Datta; Heike Löser; Yue Zhao; Alexander Quaas; Philipp Lohneis; Christiane J Bruns
Journal:  Cancers (Basel)       Date:  2021-05-29       Impact factor: 6.639

Review 10.  Detection of Immune Checkpoint Receptors - A Current Challenge in Clinical Flow Cytometry.

Authors:  Benjamin Shibru; Katharina Fey; Stephan Fricke; André-René Blaudszun; Friederike Fürst; Max Weise; Sabine Seiffert; Maria Katharina Weyh; Ulrike Köhl; Ulrich Sack; Andreas Boldt
Journal:  Front Immunol       Date:  2021-07-01       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.